ATNX News and Press, Athenex Inc. From 12/15/20

Klisyri ® is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by ...

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis EXTON, Pa. , Dec. 15, 2020 /PRNewswire/ -- Almirall, S.A. (BME:ALM) , a global biopharmaceutical company focused on skin health, announc...

Athenex ([[ATNX]] -4.2%) has announced presentation of updated Phase 3 progression free ((PFS)) and overall survival ((OS)) data, demonstrating clinical benefits in efficacy and tolerability of oral paclitaxel vs. IV paclitaxel ((IVP)) in patients with metastatic breast cancer. Data were...

Data presented at SABCS indicates benefits of oral paclitaxel and encequidar (oral paclitaxel) versus IV paclitaxel (IV P ) on Progression-Free Survival (PFS) and on Overall Survival (OS), which suppor ts superiority o n ...

BUFFALO, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athen...

S potlight p oster on updated PFS and OS data from the pivotal Phase 3 clinical trial of o ral p aclitaxel in metastatic breast cancer BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopha...

The following slide deck was published by Athenex, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Athenex, Inc. 2020 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Athenex, Inc. (NASDAQ: ATNX) Q3 2020 Earnings Call Nov 7, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Athenex, Inc. (ATNX) Q3 2020 Earnings Call Transcript

FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and February 28, 2021, respectively Four abstracts featuring Oral Paclitaxel accepted for presen...

Collegium Pharmaceuticals (NASDAQ: COLL) and Athenex (NASDAQ: ATNX) may not be the most popular stocks on the market in terms of media coverage, but both might just make you rich with a well-timed investment. Unlike many of their compatriots in the world of small market cap ...